SEC Comment Letter for Neurogene Inc. (NGNE) (CIK 0001404644) (NGNE) — Dec 29, 2015
Neurogene Inc. (NGNE) (CIK 0001404644)
Date: Dec. 29, 2015 · CIK: 0001404644 · Accession: 0000000000-15-059727
AI Filing Summary & Sentiment
File numbers found in text: 333-208651
Letter
Mail Stop 4720 December 29, 2015 Via E -mail David J. Main President and Chief Executive Officer Aquinox Pharmaceuticals, Inc. 450-887 Great Northern Way Vancouver, B.C., Canada V5T 4T5
Re: Aquinox Pharmaceuticals , Inc. Registration Statement on Form S-3 Filed December 21, 2015 File No. 333-208651
Dear Mr. Main :
This is to advise you that we have not reviewed and will not review your registration statement .
We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Act of 193 3 and all applicable Securities Act rules require. Since the company and its management are in possession of all facts relating to a company’s disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made.
In the event you request acceleration of t he effective date of the pending regist ration statement , please provide a written statement from the company acknowledging that:
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclos e the Commission from taking any action with respect to the filing;
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the ad equacy and accuracy of the disclosure in the filing; and
the company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the Unit ed States.
David J. Main Aquinox Pharmaceuticals , Inc. December 29, 2015 Page 2
Please refer to Rules 460 and 461 regarding requests for acceleration . We will consider a written request for acceleration of the effective date of the registration statement as confirmation of the fact that those requesting acceleration are a ware of their respective responsibilities under the Securities Act of 1933 and the Securities Exchange Act of 1934 as they relate to the proposed public offering of the registered securities .
You may contact Scot Foley at (202) 551 -3383 or me at (202) 551-3675 with any questions.
Sincerely,
/s/ Suzanne Hayes
Show Raw Text
Mail Stop 4720 December 29, 2015 Via E -mail David J. Main President and Chief Executive Officer Aquinox Pharmaceuticals, Inc. 450-887 Great Northern Way Vancouver, B.C., Canada V5T 4T5 Re: Aquinox Pharmaceuticals , Inc. Registration Statement on Form S-3 Filed December 21, 2015 File No. 333-208651 Dear Mr. Main : This is to advise you that we have not reviewed and will not review your registration statement . We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Act of 193 3 and all applicable Securities Act rules require. Since the company and its management are in possession of all facts relating to a company’s disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made. In the event you request acceleration of t he effective date of the pending regist ration statement , please provide a written statement from the company acknowledging that: should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclos e the Commission from taking any action with respect to the filing; the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the ad equacy and accuracy of the disclosure in the filing; and the company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the Unit ed States. David J. Main Aquinox Pharmaceuticals , Inc. December 29, 2015 Page 2 Please refer to Rules 460 and 461 regarding requests for acceleration . We will consider a written request for acceleration of the effective date of the registration statement as confirmation of the fact that those requesting acceleration are a ware of their respective responsibilities under the Securities Act of 1933 and the Securities Exchange Act of 1934 as they relate to the proposed public offering of the registered securities . You may contact Scot Foley at (202) 551 -3383 or me at (202) 551-3675 with any questions. Sincerely, /s/ Suzanne Hayes Suzanne Hayes Assistant Director Office of Healthcare and Insurance cc: Michael E. Tenta Alan D. Hambelton Cooley LLP 3175 Hanover Street Palo Alto, CA 94304